Danaher's $5.7 Billion Acquisition of Abcam Raises Investor Concerns
Danaher has announced its acquisition of biotech company Abcam in a $5.7 billion deal, which has received mixed reactions from investors due to the premium involved.
Tag
Abcam
All articles tagged with #abcam
Danaher's Acquisition of Abcam: A Game-Changing Deal
Danaher Corporation has announced its plans to acquire Abcam plc, a global supplier of protein consumables, for $5.7 billion. Abcam will operate as a standalone company within Danaher's Life Sciences segment, aligning with Danaher's strategy to advance drug discovery and diagnostics. The acquisition is expected to close in mid-2024, subject to regulatory approvals and shareholder approval.